Sponsor considered no further meaningful data was being collected, nor were likely to be collected in the future.

Patients who were previously enrolled in Study IMM-101-001 and who provided informed consent were eligible to participate in this study.

Once eligibility was confirmed, a full medical history covering the period from completion of Study IMM-101-001 to date was taken.

The treatment regimen with IMM-101 was one dose given every 4 weeks or as close to this interval as permitted due to practical or logistic considerations. The dose interval could be modified at the discretion of the Investigator provided the minimum period between doses was no less than 14 days.

The overall objective was to determine the long term safety profile of IMM-101 administered intradermally for extended use.

This was an open-label long term follow up study. The study consisted of two phases:

1. Screening and enrolment Patients, who provided informed consent participated in a screening period of up to 28 days to establish eligibility. Once eligibility was confirmed a full disease and treatment history covering the period from their completion of Study IMM-101-001 to date was taken.
2. Treatment Patients could receive ongoing treatment every 4 weeks or as close to this interval as permitted due to practical or logistic considerations until death or withdrawal, unless such therapy was contraindicated, the patient did not wish to continue or the study was terminated by the Sponsor. At no point could the elapsed period between IMM-101 doses be less than 14 days.

Patients could choose to withdraw from the study at any time and for any reason. IMM-101 could be stopped or the dosing regimen reduced if felt to be necessary by the Investigator and/or patient (e.g., intolerable injection site reactions).

In the event of an injection site reaction of Grade 3 and above, and/or if significant ulceration, tenderness or lymphadenopathy was observed, at the discretion of the Investigator, patients could be administered a half dose of the study drug (i.e., a single 0.05 mL intradermal injection of IMM-101) or the timing of the injection could be delayed. If the dosing interval was increased, the patient still attended the study site for safety assessments preferably every 3 months but, if this was not possible, every 6 months at a minimum. The blood sample for exploratory analysis continued to be taken every 6 months.

Any change in the dose of study drug administered or the frequency of dose administration was recorded in the patient's case report form (CRF). In the case of withdrawal, separate consent was sought to allow the continued collection on patient status.

Inclusion Criteria:

• Patient was previously enrolled in Study IMM-101-001
• Patient gave consent to make their disease and treatment history for the intervening period between their completion of Study IMM-101-001 and enrollment in this study available to the Sponsor
• Patient gave signed informed consent for participation in the study

Exclusion Criteria:

• Female patient of child-bearing potential who was not, in the opinion of the Investigator, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).

Those patients that utilised hormonal contraceptives must have used the same method for at least three months before additional barrier contraception (as described above) was discontinued from being used concomitantly with the hormonal contraception.

• Patient of non-child-bearing potential were defined as having 12 month amenorrhoea or were surgically sterile.
• Female patient who was pregnant, breast feeding or planning a pregnancy during the course of the study. A pre-treatment urine pregnancy test measuring human chorionic gonadotrophin (hCG) must be negative.
• Patient was unable or unwilling to comply with the protocol.

All enrolled patients

Adverse events were collected from the time of informed consent until study completion (median 4.4 years, range 1.2 - 6.7)

Adverse events (including those reported spontaneously by the patient, observed by the Investigator or elicited using non-leading questions) were collected from the time of signing informed consent until 30 days after the end of study or withdrawal.

Adverse event information could be obtained during study visits or by telephone contact with the patient between visits.

The median survival time was not calculable as less than 50% patients died. No inferences can be made from the rate of survival due to the small sample size.

Given the fact patients could receive anti-cancer therapy on study, disease status fluctuated throughout the study (better, worse, no change). This coupled with the sparsity of CT or MRI scan data collected on a per patient basis resulted in only Best Overall Response being described.